Printer Friendly

IMCERA'S MALLINCKRODT MEDICAL UNIT SUBMITS NEW DRUG APPLICATION TO FDA FOR CANCER IMAGING AGENT

 IMCERA'S MALLINCKRODT MEDICAL UNIT SUBMITS
 NEW DRUG APPLICATION TO FDA FOR CANCER IMAGING AGENT
 NORTHBROOK, Ill., Oct. 23 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that its Mallinckrodt Medical unit of St. Louis has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for an imaging agent developed for the early diagnosis of certain types of cancers.
 The new agent, called OctreoScan(TM) 111, is designed to help physicians detect and locate small tumors and their metastases in many parts of the body. The agent also may help physicians determine the presence of new tumors after patients have undergone surgical removal of original tumors. The FDA New Drug Application is specifically for the use of the agent to detect tumors that originate from neuro-endocrine cells, found primarily in the abdominal area of the body.
 "If approved by the FDA, OctreoScan 111 will become an important part of our diagnostic radiopharmaceutical product line," said Ray Holman, president and chief executive officer of Mallinckrodt Medical. "This is the first indication for OctreoScan 111 we are seeking. There are some other, even more exciting, applications for this drug we are investigating and considering."
 The imaging agent was developed by Mallinckrodt Medical in conjunction with the University Hospital Dijkzigt in Rotterdam, Holland, and Sandoz Pharma Ltd. of Basel, Switzerland. It will be manufactured in St. Louis and Petten, Holland.
 The OctreoScan 111 kit combines Indium-111, an isotope with excellent tumor-imaging qualities, with a modified version of the drug octreotide, introduced by Sandoz in 1988 under the name SandostatinR. Octreotide is an analogue of somatostatin, a peptide which naturally occurs in the human body.
 Research scientists Dr. Rainer Albert and Dr. Janos Pless at Sandoz and Professors Eric Krenning and Steven Lamberts at Rotterdam discovered that the radioisotope-labeled octreotide derivative appears to bind to many tumor cells with somatostatin receptors, making these tumors potentially more detectable at an early stage. Studies have shown that more than 80 percent of neuro-endocrine tumors in patients have somatostatin receptors.
 "We have been able to visualize remarkably small tumor cells in many parts of the body," said Professor Krenning, who heads the nuclear medicine department at Rotterdam.
 Once detected, neuro-endocrine tumors may be excellent candidates for octreotide therapy.
 "The radiolabeling of small peptides is a new technology that may open a whole new area of diagnosis in oncology," said William J. Mercer, Mallinckrodt Medical senior vice president and group executive. "This is the first radiolabeled peptide submitted for FDA approval specifically for tumor imaging."
 The New Drug Application was submitted to the FDA's Center for Drug Evaluation and Research.
 OctreoScan 111 has undergone human clinical trials in Europe, where approval is being sought. Mallinckrodt Medical also plans to apply for approval in Canada and Japan.
 Mallinckrodt Medical is a leading producer of radiopharmaceuticals in the $800 million worldwide nuclear medicine market, which is expected to grow to about $1.1 billion by 1995. Mallinckrodt also operates a network of nuclear medicine pharmacies in 30 key markets across the United States and Canada.
 With fiscal 1992 net worldwide sales of $620 million and operating earnings of $128 million, Mallinckrodt Medical is a major supplier of products for radiology, cardiology, nuclear medicine, anesthesiology and critical care. Its products are sold in more than 100 countries and used by more than 7,000 health care facilities in the U.S.
 IMCERA, a Fortune 250 company with fiscal 1992 net sales of more than $1.7 billion, has two other international, technology-based businesses -- Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Lake Forest, Ill.
 -0- 10/23/92
 /CONTACT: Dave Prichard of IMCERA Group Inc., 708-205-2270/
 (IMA) CO: IMCERA Group Inc. ST: Illinois IN: MTC SU:


TS -- NY008 -- 4014 10/23/92 09:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 23, 1992
Words:629
Previous Article:SPECIALISTS IN AGING GATHER IN BOSTON
Next Article:ASHLAND COAL BOARD APPROVES QUARTERLY DIVIDEND
Topics:


Related Articles
IMCERA'S MALLINCKRODT MEDICAL UNIT RECEIVES APPROVAL OF OPTIRAY X-RAY CONTRAST MEDIA IN JAPAN
IMCERA'S MALLINCKRODT MEDICAL UNIT INTRODUCES ULTRAJECT PREFILLED SYRINGE IN GERMANY
IMCERA'S MALLINCKRODT MEDICAL ANNOUNCES $15 MILLION EXPANSION AT RALEIGH, N.C., PLANT
MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT ANNOUNCE FILING OF NDS FOR ALBUNEX(R)
FDA ADVISORY PANEL RECOMMENDS APPROVAL FOR MBI'S ALBUNEX(R)
MOLECULAR BIOSYSTEMS INC. SUBMITS PMA AMENDMENT TO FDA
OCTREOSCAN 111 FROM IMCERA'S MALLINCKRODT MEDICAL UNIT RECOMMENDED FOR MARKETING BY FDA MEDICAL IMAGING DRUGS ADVISORY COMMITTEE
ALBUNEX(R) RECEIVES FDA APPROVAL; FIRST CONTRAST AGENT FOR ULTRASOUND
MALLINCKRODT MEDICAL SUBMITS NDA FOR NEW CANCER PAIN AGENT
MOLECULAR BIOSYSTEMS, MALLINCKRODT GROUP ANNOUNCE NEW ALLIANCE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters